1,149 results on '"Grever, Michael R."'
Search Results
2. Evaluation of bleeding events in patients receiving acalabrutinib therapy
3. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
4. Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib
5. Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia.
6. Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy
7. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia
8. Clinical Development of 2′-Deoxycoformycin
9. Second cancer incidence in CLL patients receiving BTK inhibitors
10. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients
11. Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
12. Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2
13. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
14. Herpes Zoster and Lymphopenia Associated with Sodium Stibogluconate Therapy for Cutaneous Leishmaniasis
15. Supplementary table 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
16. Supplementary Tables 1-2 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
17. Supplementary table 2 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
18. supplemental legend from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
19. Supplementary Figure Legends from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
20. Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
21. Supplementary figure 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
22. Two-inhibitor salvage therapy for hairy cell leukemia
23. Pharmaceutical Prospecting and the Potential for Pharmaceutical Crops. Natural Product Drug Discovery and Development at the United States National Cancer Institute
24. Historical overview of hairy cell leukemia
25. BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation
26. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
27. FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia
28. Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment
29. Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study
30. Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues
31. Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL
32. Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia
33. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib
34. Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
35. Hairy cell leukemia: Update on molecular profiling and therapeutic advances
36. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy
37. Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.
38. Racial and socioeconomic disparities among patients with chronic lymphocytic leukemia: Analysis of Surveillance, Epidemiology, and End Results program data.
39. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
40. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia
41. Sorbicillinoid analogs with cytotoxic and selective anti-Aspergillus activities from Scytalidium album
42. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
43. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
44. The Role of Plants in the Drug Discovery Program of the United States National Cancer Institute
45. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
46. Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib
47. Characterization of Cytotoxic Macrophages in a Pre-Clinical Model of Epstein-Barr Virus (EBV)-Driven Lymphoproliferative Disease
48. Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status
49. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
50. How I treat hairy cell leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.